Status:
COMPLETED
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
Lead Sponsor:
Lux Biosciences, Inc.
Conditions:
Uveitis, Anterior
Panuveitis
Eligibility:
All Genders
13+ years
Phase:
PHASE3
Brief Summary
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis
Eligibility Criteria
Inclusion
- Documented history of non-infectious anterior, anterior and intermediate- or panuveitis
- Currently uncontrolled uveitis for a minimum of 2 weeks despite use of oral and/or topical corticosteroid,or subjects who are intolerant of local corticosteroid therapy due to the development of an ocular hypertensive response or subjects for whom oral corticosteroid is contraindicated.
- Grade of 2+ or higher for anterior chamber cells at time of enrollment
- Considered by the investigator to require corticosteroid-sparing therapy.
- Subjects not planning to undergo elective ocular surgery during the study
Exclusion
- Uveitis of infectious etiology
- Presence of an ocular toxoplasmosis scar
- An immune suppression regimen that includes an alkylating agent within the previous 90 days
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT00404885
Start Date
January 1 2007
End Date
May 1 2009
Last Update
June 22 2012
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States
2
Retinal Consultants of Arizona
Phoenix, Arizona, United States, 85014
3
University of Illinois - Chicago
Chicago, Illinois, United States, 60612
4
Wilmer Eye Institute
Baltimore, Maryland, United States, 21287